DM4

Catalog No.E7058 Batch:E705801

Technical Data

Formula

C₃₈H₅₄ClN₃O₁₀S

Molecular Weight

780.37

CAS No.

796073-69-3

Solubility (25°C)*

In vitro

Ethanol

50 mg/mL (64.07 mM)

DMSO

20 mg/mL (25.62 mM)

Water

Insoluble

In vivo (Add solvents to the product individually and in order)

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1mg/ml (1.28mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	DM4 is a potent maytansinoid and potent inhibitor of tubulin. It binds to α/β-tubulin heterodimers and inhibits tubulin polymerization and microtubule assembly, leading to enhanced microtubule destabilization. This strong antimitotic activity results in suppressed microtubule dynamics, causing mitotic arrest and apoptotic cell death, making it valuable for studying acute myeloid leukemia (AML) therapies.

Description

DM4 is a potent maytansinoid and potent inhibitor of tubulin. It binds to α/β-tubulin heterodimers and inhibits tubulin polymerization and microtubule assembly, leading to enhanced microtubule destabilization. This strong antimitotic activity results in suppressed microtubule dynamics, causing mitotic arrest and apoptotic cell death, making it valuable for studying acute myeloid leukemia (AML) therapies.

Protocol (from reference)

References

https://pubmed.ncbi.nlm.nih.gov/19549303/

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.